Search results for "Survival."

showing 10 items of 3280 documents

Lebermetastasen kolorektaler Karzinome - wie oft kann man operieren?

2007

Recurrent liver metastases of colorectal carcinoma are frequent. The repeat hepatectomy is superior to other therapeutic options. In about 20 % of patients with recurrent liver metastases a complete resection (R 0) is possible. The morbidity of repeat hepatectomy is similar to that of first hepatectomy. The 5-year survival rate after repeat hepatectomy ranges between 30 and 40 %. Often in the follow-up additional operations become necessary for extrahepatic recurrencies. For determination of the optimal therapy an interdisciplinary approach must be chosen.

medicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentRepeat hepatectomymedicine.diseaseComplete resectionSurgeryText miningmedicineSurgeryOperative therapyHepatectomybusinessSurvival rateZentralblatt für Chirurgie
researchProduct

Synthesis, Anti-Inflammatory Activity, and in Vitro Antitumor Effect of a Novel Class of Cyclooxygenase Inhibitors: 4-(Aryloyl)phenyl Methyl Sulfones

2010

Following our previous research on anti-inflammatory drugs (NSAIDs), we report on the design and synthesis of 4-(aryloyl)phenyl methyl sulfones. These substances were characterized for their capacity to inhibit cyclooxygenase (COX-1 and COX-2) isoenzymes. Molecular modeling studies showed that the methylsulfone group of these compounds was inserted deep in the pocket of the human COX-2 binding site, in an orientation that precludes hydrogen bonding with Arg120, Ser353, and Tyr355 through their oxygen atoms. The N-arylindole 33 was the most potent inhibitor of COX-2 and also the most selective (COX-1/COX-2 IC(50) ratio was 262). The indole derivative 33 was further tested in vivo for its ant…

Models MolecularIndolesMolecular modelCell SurvivalStereochemistrymedicine.drug_classAntineoplastic AgentsAnti-inflammatoryStructure-Activity RelationshipIn vivoCell Line TumorDrug DiscoverymedicineAnimalsHumansCyclooxygenase InhibitorsSulfonesBinding siteIC50Cell ProliferationIndole testCyclooxygenase 2 InhibitorsbiologyChemistryStereoisomerismSettore CHIM/08 - Chimica FarmaceuticaIn vitroRats4-(Aryloyl)phenyl methyl sulfones anti-inflammatory activity antitumor effect COX-1/COX-2 selectivityCyclooxygenase 1biology.proteinThermodynamicsMolecular MedicineCyclooxygenaseDrug Screening Assays AntitumorHydrophobic and Hydrophilic InteractionsJournal of Medicinal Chemistry
researchProduct

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…

2018

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…

OncologyReceptor ErbB-2Settore MED/06 - Oncologia Medicaletrozolelaw.inventionAdjuvant anastrozolechemistry.chemical_compound0302 clinical medicineRandomized controlled trialExemestanelawAdjuvant anastrozole; exemestane; letrozole; tamoxifen; breast cancerAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicinetamoxifenAromatase InhibitorsLetrozoleHazard ratioMiddle AgedReceptors EstrogenTolerabilityOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleReceptors ProgesteroneBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtySocio-culturaleAnastrozoleBreast NeoplasmsAnastrozoleDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineAromatase InhibitorHumansAgedAntineoplastic Combined Chemotherapy ProtocolAndrostadienebusiness.industrymedicine.diseaseAndrostadieneschemistrybusinessexemestaneTamoxifen
researchProduct

Body mass index as a predictor of all-cause mortality in nursing home residents during a 5-year follow-up.

2013

Background: Body mass index (BMI) is considered a short-term mortality predictor, but a consensus has not been reached on its role and that of other nutritional parameters in predicting long-term mortality in nursing home residents. Objectives: To correlate BMI, Mini Nutritional Assessment scores, and serum albumin levels with the 5-year mortality rate in institutionalized elderly subjects. Methods: A total of 181 nursing home residents aged ≥70 years were included in a 5-year longitudinal study. Data were collected on all participants' nutritional, health, cognitive, and functional status by means of a comprehensive geriatric assessment. Data on the participants' vital status were obtained…

GerontologyMaleLongitudinal studyComorbiditySeverity of Illness IndexBody Mass IndexPredictive Value of TestsCause of DeathMedicineHumansLongitudinal StudiesBody mass index nursing home mortality elderly nutritionGeriatric AssessmentGeneral NursingSurvival analysisCause of deathAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelHealth PolicyMortality rateGeneral Medicinemedicine.diseaseComorbidityNursing HomesPredictive value of testsLinear ModelsFemaleGeriatrics and GerontologybusinessBody mass indexDemographyFollow-Up StudiesJournal of the American Medical Directors Association
researchProduct

Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients.

2013

ObjectiveOur study purpose was to evaluate morbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies.MethodsWe identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charitè University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso.ResultsThe median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performe…

Adultmedicine.medical_specialtyGenital Neoplasms Femalemedicine.medical_treatmentYoung AdultRetrospective StudieGermanymedicineHumansPostoperative PeriodMortalityAgedRetrospective StudiesAged 80 and overCervical cancerVaginal cancerHysterectomyGynecological malignanciePelvic exenterationbusiness.industryEndometrial cancerMortality rateGynecological malignanciesObstetrics and GynecologyPerioperativeMiddle AgedVulvar cancermedicine.diseaseSurvival AnalysisPelvic ExenterationSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncologyFemaleSurvival AnalysiMorbidityMorbidity pelvic exenteration gynecological malignanciesbusinessHuman
researchProduct

Early Plasmodium-induced inflammation does not accelerate aging in mice

2019

10 pages; International audience; Aging is associated with a decline of performance leading to reduced reproductive output and survival. While the antagonistic pleiotropy theory of aging has attracted considerable attention, the molecular/physiological functions underlying the early-life benefits/late-life costs paradigm remain elusive. We tested the hypothesis that while early activation of the inflammatory response confers benefits in terms of protection against infection, it also incurs costs in terms of reduced reproductive output at old age and shortened longevity. We infected mice with the malaria parasite Plasmodium yoelii and increased the inflammatory response using an anti-IL-10 r…

0106 biological sciences0301 basic medicineSenescencesenescencemedia_common.quotation_subjectlcsh:EvolutionInflammationBiologysourisantagonistic pleiotropy010603 evolutionary biology01 natural sciencessurvival03 medical and health sciencesPlasmodium malariaePleiotropyBiologie animaleGeneticsmedicinelcsh:QH359-425Survival rateEcology Evolution Behavior and Systematicsmedia_commonAnimal biology[SDV.BA]Life Sciences [q-bio]/Animal biologyLongevityAntagonistic pleiotropy hypothesisPlasmodium yoeliimedicine.diseasebiology.organism_classificationinfection3. Good healthsurvie030104 developmental biologyinflammationImmunology[SDV.IMM]Life Sciences [q-bio]/ImmunologyAntagonistic pleiotropyantagonistic pleiotropy;inflammation;Plasmodium yoelii;senescence;survivalmedicine.symptom[SDE.BE]Environmental Sciences/Biodiversity and EcologyGeneral Agricultural and Biological SciencesMalariaPlasmodium yoelii
researchProduct

Monochorionic twin pregnancy: screening, pathogenesis of complications and management in the era of microinvasive fetal surgery

2010

Objective The management of monochorionic (MC) twin pregnancies varies in different medical centers. This paper compares screening methods to predict the complications of the MC twin pregnancy and different treatment methods. Methods We performed a literature search without language restriction in Cochrane library and PubMed (1970-2009). Case series and cohort screening studies, pathogenesis and management of complications of MC pregnancy were included. Results Elevated risk for intrauterine fetal death (IUFD) and twin-to-twin transfusion syndrome (TTTS) can be detected sonographically. Monitoring of MC pregnancies at increased risk and regular training sessions for the operating team combi…

Malemedicine.medical_specialtymedicine.medical_treatmentPrenatal diagnosisModels BiologicalPregnancyPrenatal DiagnosismedicineHumansAmnionNeonatologySurvival rateTwin PregnancyUltrasonographyFetal TherapiesPregnancyFetal Growth RetardationLaser CoagulationFetal surgeryObstetricsbusiness.industryInfant NewbornObstetrics and GynecologyChorionFetofetal TransfusionTwins Monozygoticmedicine.diseasePregnancy ComplicationsPediatrics Perinatology and Child HealthFemaleMonochorionic twinsPregnancy MultiplebusinessLaser coagulationJournal of Perinatal Medicine
researchProduct

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diff use large B-cell lymphoma: comparison b…

2015

Summary Background Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collab…

AdultMalePathologymedicine.medical_specialtyPediatricsAdolescent[SDV]Life Sciences [q-bio]Follicular lymphomaAutopsyNOminimum clinical recommendations03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicinefollow upHumans030212 general & internal medicineYoung adultcancer survivalLymphoma FollicularNon-Hodgkin lymphomaAgedHematologyWalesminimum clinical recommendations Non-Hodgkin lymphoma relative survival cancer survival follow upbusiness.industryCancerrelative survivalHematologyMiddle Agedmedicine.disease3. Good healthLymphoma[SDV] Life Sciences [q-bio]EuropeScotland030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaInternational Classification of Diseases for Oncology
researchProduct

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct